MKMichio Kimura

Michio Kimura

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michio Kimura has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Baseline Peripheral Neuropathy Predicts Clinically Significant Neuropathy During Paclitaxel Treatment Following Oxaliplatin-based Chemotherapy

    by Aiko Tomiuchi, Michio Kimura, Yoshiaki Ikeda, Eiseki Usami

    Background/Aim: Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting toxicity that adversely affects quality of life and treatment continuity of patients with malignancy. Although cumulative oxaliplatin exposure is a recognized risk factor for neurotoxicity, it remains unclear whether cumulative exposure or baseline neurological status better predicts clinically significant CIPN during subsequent paclitaxel treatment. This study aimed to identify predictors of clinically significant CIPN during paclitaxel therapy, focusing on the relative predictive value of cumulative oxaliplatin exposure and baseline CIPN. Patients and Methods: We retrospectively reviewed 76 patients with advanced gastric cancer who received paclitaxel-based second-line therapy after oxaliplatin-containing first-line chemotherapy. The primary endpoint was time to development of grade ≥2 CIPN, and the secondary endpoint was CIPN worsening. Cox proportional hazards and multivariable logistic regression analyses were performed to identify factors associated with CIPN progression. Results: Grade ≥2 CIPN developed in 34 patients (44.7%). Baseline CIPN (grade 1 vs. 0) independently predicted subsequent grade ≥2 CIPN (hazard ratio=4.23, 95% confidence interval=1.67-10.72; p=0.002; odds ratio=5.00, 95% confidence interval=1.58-15.80; p=0.006). In contrast, cumulative oxaliplatin dose was not associated with grade ≥2 CIPN or CIPN worsening. Kaplan–Meier analysis also showed no association between cumulative oxaliplatin dose and time to CIPN worsening, whereas higher serum albumin levels tended to be associated with a lower risk of CIPN progression. Conclusion: Baseline CIPN was a stronger predictor of clinically significant neuropathy during paclitaxel treatment than prior cumulative oxaliplatin exposure. Routine assessment of baseline neurological status before paclitaxel initiation may help identify patients at high risk for clinically significant CIPN and support individualized treatment and monitoring strategies.

  • Open Access

    Analysis of Opioid Disposal in Hospitalized Patients According to Dosage Form, Dose, Cost, and Admission Type: A Retrospective Study

    by Nanami Ogura, Michio Kimura, Eri Anbe, Kayo Ito, Norio Suzuki, Eiseki Usami

    A BSTRACT: Objective: Opioids are essential for cancer pain management but often require dose or route adjustments, leading to disposal of unused medications. This study investigated opioid disposal by dosage form, dose, economic impact, and admission type. Methods: This retrospective observational study included patients who received oral or transdermal opioids at Ogaki Municipal Hospital between January 2023 and December 2024. Opioid disposal, defined as nonreusable opioids discarded according to narcotics management records, was identified retrospectively. Disposal volume, cost, and reasons for disposal were evaluated. Costs were calculated using official drug prices (April 2025). Associations between admission type and disposal reasons were analyzed using the Chi-square test. Findings: Eighty-eight patients experienced opioid disposal. The total disposal volume was 3022 units, with a total cost of JPY 599,736 (mean: JPY 6815 per patient). Disposal frequently involved low-dose oral opioid formulations, particularly sustained-release oxycodone (5, 10 mg). Pareto analysis showed that the top five drugs accounted for 59.5% of total disposal costs. Disposal reasons differed significantly by admission type ( χ 2 = 40.8, df = 4, P < 0.001): death-related disposal occurred only in emergency admissions, whereas planned admissions were more frequently associated with drug changes and represcriptions. Conclusion: Opioid disposal in hospitalized patients occurs frequently, including with low-dose oral formulations. Costs are concentrated in a limited number of drugs and vary by admission type. Optimizing opioid selection and early assessment of administration routes may help reduce unnecessary disposal while maintaining adequate pain control.

  • Open Access

    Factors Contributing to Increased Fall Risk in Patients Administered Orexin Receptor Antagonists

    by Koki Mori, Michio Kimura, Eiseki Usami

    Background and Objective Orexin receptor antagonists (ORAs) are increasingly used as hypnotic sedatives. Compared to γ-aminobutyric acid receptor agonists, ORAs lack muscle-relaxant properties and are associated with a lower risk of falls. However, falls do occur in small numbers. We aimed to determine factors correlated with fall risk in patients administered ORAs.Methods Data of hospitalized patients administered suvorexant or lemborexant between January 1, 2022 and December 31, 2023 were retrospectively analyzed. Patients already taking medications upon hospitalization and those with unknown height or weight were excluded. Falls were identified through incident reports. Propensity-score matching was conducted based on demographics and clinical background, followed by statistical analysis. Logistic regression was applied to factors with p<0.2.Results Of 2,348 patients, 1,324 were eligible for analysis. After propensity-score matching, 66 patients were in the falls group and 132 in the non-falls group. Antidepressant use was significantly more common in the falls group (p=0.017) than in the non-falls group. Antidepressant use was associated with increased fall risk (odds ratio [OR], 14.40; p=0.016), whereas comorbid depression was protective (OR, 0.04; p=0.022). No significant associations were found for lemborexant use, benzodiazepine use, heart failure, or schizophrenia.Conclusions Antidepressants increase fall risk in ORA users, whereas comorbid depression may prevent falls.

  • Open Access

    Impact of TAS‑102 dose reduction on severe neutropenia and survival outcomes in patients with metastatic colorectal cancer and prior chemotherapy‑induced neutropenia

    by Chihiro Suzuki, Michio Kimura, Makiko Go, Yoshiaki Ikeda, Eiseki Usami

    The present study aimed to evaluate the impact of initial dose reduction of trifluridine/tipiracil (TAS‑102) monotherapy on the incidence of severe neutropenia and overall survival (OS) in individuals with metastatic colorectal cancer, considering prior chemotherapy‑induced severe neutropenia. Participants were classified into the following three groups: A group, individuals who did not experience severe neutropenia during previous chemotherapy and did not undergo dose reduction (n=61); B1 group, those who experienced severe neutropenia during previous chemotherapy and received an initial dose reduction of TAS‑102 (n=28); and B2 group, those who experienced severe neutropenia but did not receive a dose reduction (n=88). Neutropenia severity, progression‑free survival (PFS) and OS were compared among the groups. Notably, there was no significant difference in the incidence of grade 3 or higher neutropenia among the three groups during TAS‑102 administration (P=0.958). The median OS times in the A group (n=61), B1 group (n=28) and B2 group (n=88) were 273 days (95% CI, 199‑299), 285 days (95% CI, 202‑NA) and 233 days (95% CI, 182‑272), respectively (log‑rank test, P=0.165). The median PFS times among the three groups were 133.0 days (95% CI, 98‑153), 94.5 days (95% CI, 77‑133) and 93.5 days (95% CI, 83‑100), respectively (log‑rank test, P=0.053). In conclusion, a proactive dose reduction at TAS‑102 treatment initiation based on pre‑existing severe neutropenia should be carefully considered, as it may not be necessary.


  • Analysis of acute pancreatitis caused by multi-acting receptor-targeted antipsychotics using the Japanese claims database

    by Yoshihiro Noguchi, Ai Oonishi, Rikuto Masuda, Koki Mori, Michio Kimura, Eiseki Usami, Tomoaki Yoshimura


  • Open Access

    Factors Influencing Severe Hematologic Toxicity Following Niraparib Therapy in Patients With Ovarian Cancer

    by Michio Kimura, Shiori Yamada, Rina Matsuyama, Makiko Go, Eiseki Usami

    Background/Aim: Niraparib is a poly ADP ribose polymerase (PARP) inhibitor indicated for the maintenance therapy of ovarian cancer and the treatment of recurrent ovarian cancer. This study aimed to identify an indicator to predict severe hematologic toxicity after niraparib therapy. Patients and Methods: We retrospectively included 32 patients with advanced ovarian cancer who were administered niraparib at Ogaki Municipal Hospital (Ogaki, Japan) between January 2020 and December 2024. Univariate analyses were performed to evaluate the relationship between the patients’ baseline characteristics and the development of severe hematologic toxicity. Significant variables in the univariate analysis, as well as age, were entered into the multivariate logistic regression model. The optimal cutoff values for significant variables were determined using receiver-operating characteristic (ROC) curve analyses. Results: Severe hematologic toxicity was independently associated with pre-treatment creatinine clearance (odds ratio=0.920; 95% confidence interval=0.823-0.998; p=0.045). The areas under the ROC curves of creatinine clearance at the time of the worst-grade hematologic toxicity before and during niraparib administration were assessed for their ability to predict severe hematologic toxicity. The area under the curves of creatinine clearance at the time of ≥grade 3 hematologic toxicity during niraparib therapy showed high accuracy, with a value of 0.809 (95% confidence interval=0.659-0.958). The calculated cutoff value using the creatinine clearance curve was 47.0 ml/min. Conclusion: Creatinine clearance is a risk factor for severe hematologic toxicity. A creatinine clearance value <47.0 ml/min may slightly increase the risk of this toxicity in patients with ovarian cancer receiving niraparib.


  • Identifying risk factors of dose reduction or treatment discontinuation due to fatigue or gastrointestinal symptoms in patients receiving lenvatinib treatment for hepatocellular carcinoma

    by Michio Kimura, Shiori Yamada, Makiko Go, Satoshi Yasuda, Hidenori Toyoda, Eiseki Usami

    Introduction: Lenvatinib (LEN) is the standard treatment for hepatocellular carcinoma (HCC). In clinical practice, gastrointestinal (GI) symptoms such as fatigue and loss of appetite often lead to dose reduction or treatment discontinuation. This study aimed to identify the predictors of patients who will experience dose reduction or treatment discontinuation owing to fatigue or GI symptoms during LEN treatment for HCC. Methods: We retrospectively identified 99 patients who received LEN at the Ogaki Municipal Hospital (Ogaki, Japan) between April 2018 and December 2023. To investigate the risk factors for treatment discontinuation or dose reduction due to fatigue or GI symptoms during LEN administration, patients were divided into two groups based on whether treatment discontinuation or dose reduction occurred due to fatigue or GI symptoms during LEN administration (37 patients) or not (62 patients). We compared baseline characteristics between the two groups. Results: Multivariate analysis revealed that body weight (odds ratio 4.310, 95% confidence interval 1.380–13.500; P = 0.002) was an independent risk factor that significantly contributed to treatment discontinuation or dose reduction owing to fatigue or GI symptoms during LEN administration. The cut-off value calculated using the body weight curve was 55.0 kg. Using this cutoff value, the sensitivity and specificity of body weight to detect treatment discontinuation or dose reduction due to fatigue or GI symptoms during LEN administration were 83.9% and 56.8%, respectively. Conclusion: In clinical practice, patients weighing less than 55 kg who start with a full dose will likely experience weight loss or discontinuation during treatment.


  • Open Access

    Safety evaluation of lenvatinib treatment after atezolizumab plus bevacizumab therapy for patients with unresectable liver cancer: A comparison of lenvatinib as 1st‑ or 2nd‑line treatment

    by Michio Kimura, Shiori Yamada, Makiko Go, Satoshi Yasuda, Hidenori Toyoda, Eiseki Usami

    Atezolizumab plus bevacizumab (Atez/BV) as first‑line therapy and lenvatinib (LEN) as second‑line therapy are the recommended treatments for patients with unresectable hepatocellular carcinoma. Adverse immune events caused by immune checkpoint inhibitors (such as Atez) generally only occur several months after administration; therefore, the potential influence of the first‑line treatment on second‑line treatment is not clear. The present study investigated the safety of second‑line LEN treatment (2nd LEN) by comparing the adverse events (AEs) of 2nd LEN after first‑line Atez/BV treatment for unresectable liver cancer, with those of first‑line LEN treatment (1st LEN). Patients who received Atez/BV as first‑line therapy and 2nd LEN, or those who received 1st LEN at Ogaki Municipal Hospital (Ogaki, Japan) between April 2018 and September 2023 were retrospectively evaluated for treatment duration and AEs. The median treatment duration for patients in the 1st LEN (n=39) and 2nd LEN (n=13) groups was 151.0 days [95% confidence interval (CI) 77‑303 days] and 128.5 days (95% CI 68‑270 days), respectively (P=0.385). A greater proportion of patients showed elevated aspartate aminotransferase/alanine aminotransferase levels in the 2nd LEN group (76.9%) compared with those in the 1st LEN group (46.2%) (P=0.016). Hypothyroidism was more common in those receiving 2nd LEN (46.2%) than 1st LEN (12.8%) (P=0.016). In addition, grade 1 (three patients) and grade 2 (three patients) hypothyroidism was observed in patients receiving 2nd LEN. For these six patients, during first‑line Atez/BV treatment, four patients had grade 0 hypothyroidism and two patients had grade 1 hypothyroidism (P=0.025). In conclusion, patients receiving 2nd LEN after treatment with Atez/BV are at an increased risk of hypothyroidism.


  • Comparison of Safety and Treatment Continuity of Palbociclib and Abemaciclib for Hormone Receptor-Positive, HER2-Negative Metastatic/Recurrent Breast Cancer

    by Makiko Go, Michio Kimura, Shiori Yamada, Eiseki Usami, Yoshihiro Noguchi, Tomoaki Yoshimura

    Background: Appropriate adverse event (AE) management and maintenance of therapeutic intensity are necessary to achieve therapeutic benefits of CDK4/6 inhibitors (palbociclib and abemaciclib) in hormone receptor-positive, HER2-negative metastatic/recurrent breast cancer. Objective: This study was aimed at clarifying the effect of AEs associated with palbociclib and abemaciclib on treatment. Methods: A total of 62 and 49 patients were prescribed palbociclib and abemaciclib, respectively, at our hospital from January 1, 2018 to June 30, 2023. The rate and reasons for treatment discontinuation, interruption of administration, and changes in dose and dosing schedule, treatment duration, and relative dose intensity (RDI) were compared between the groups of patients prescribed the 2 treatments. Results: Treatment discontinuation due to AEs occurred more frequently with abemaciclib (12 patients) because of interstitial lung disease and hepatic and renal events than with palbociclib (5 patients; P = .008). Administration was interrupted in 57 (91.9%) and 35 (71.4%) patients treated with palbociclib and abemaciclib, respectively ( P = .004). Dose reduction occurred in 37 (67.3%) and 19 (47.5%) patients treated with palbociclib and abemaciclib, respectively ( P = .053). The median [range] treatment duration was 301 [21-1643] days for palbociclib and 238 [70-1526] days for abemaciclib (log-rank test, P = .581). The median RDI was 59.7% and 59.6% for palbociclib and abemaciclib, respectively ( P = .539). Although the AEs of palbociclib and abemaciclib affected the treatment considerably, the treatment duration and RDI were similar. Conclusion: CDK4/6 inhibitors should be selected based on the tolerability and manageability of each AE.